VABIOTECH
State-owned Vietnamese enterprise focused on research, development, manufacture, registration and distribution of vaccines and biological products, and on delivery of vaccination services. Operates WHO-GMP manufacturing facilities with biosafety systems, conducts vaccine R&D and clinical trials, manages technology transfer and international collaborations, and maintains cold-chain infrastructure for storage and clinic delivery.
Industries
Nr. of Employees
small (1-50)
Products
Locally manufactured vaccines
Range of domestically produced vaccines including inactivated virus vaccines, recombinant subunit vaccines and oral bacterial vaccines used in national and private immunization programs.
Imported vaccines and blood-derived products (distribution)
Distribution and commercialization of imported vaccines (combination and monovalent vaccines) and blood-derived biologicals to supplement the domestic portfolio and meet clinical demand.
HAVAX® Vắc xin viêm gan A
Vi rút viêm gan A (chủng HM 175) nuôi cấy trên tế bào thận khỉ, tinh chế và bất hoạt bằng formaldehyde, là hỗn dịch vô trùng chứa vi rút viêm gan A hấp phụ với hydroxyt nhôm.
Vắc xin
Vắc xin bất hoạt phòng bệnh viêm não Nhật Bản trên tế bào Vero, chủng Beijing-1, có dạng đa liều và đơn liều.
Vắc xin phòng bệnh thuỷ đậu
Vắc xin phòng bệnh thuỷ đậu nhập khẩu và chuyển giao công nghệ.
Vắc xin phòng bệnh dại
Vắc xin phòng bệnh dại nhập khẩu và chuyển giao công nghệ.
Locally manufactured vaccines
Range of domestically produced vaccines including inactivated virus vaccines, recombinant subunit vaccines and oral bacterial vaccines used in national and private immunization programs.
Imported vaccines and blood-derived products (distribution)
Distribution and commercialization of imported vaccines (combination and monovalent vaccines) and blood-derived biologicals to supplement the domestic portfolio and meet clinical demand.
HAVAX® Vắc xin viêm gan A
Vi rút viêm gan A (chủng HM 175) nuôi cấy trên tế bào thận khỉ, tinh chế và bất hoạt bằng formaldehyde, là hỗn dịch vô trùng chứa vi rút viêm gan A hấp phụ với hydroxyt nhôm.
Vắc xin
Vắc xin bất hoạt phòng bệnh viêm não Nhật Bản trên tế bào Vero, chủng Beijing-1, có dạng đa liều và đơn liều.
Vắc xin phòng bệnh thuỷ đậu
Vắc xin phòng bệnh thuỷ đậu nhập khẩu và chuyển giao công nghệ.
Vắc xin phòng bệnh dại
Vắc xin phòng bệnh dại nhập khẩu và chuyển giao công nghệ.
Services
Routine immunizations, travel vaccinations and seasonal vaccines delivered at company-operated vaccination centers with cold-chain maintained vaccines and post-vaccination observation.
Routine immunizations, travel vaccinations and seasonal vaccines delivered at company-operated vaccination centers with cold-chain maintained vaccines and post-vaccination observation.
Expertise Areas
- Vaccine manufacturing
- Vaccine platform R&D (inactivated, recombinant, conjugate, viral vectors)
- Clinical trial management
- Regulatory affairs and dossier preparation
Key Technologies
- Cell-based antigen production (Vero cells; primary monkey kidney cells)
- Recombinant subunit expression (yeast-based systems)
- Polysaccharide–protein conjugation
- Viral vector vaccine platforms
News & Updates
Completed Phase II clinical trial for a seasonal influenza A/H5N1 vaccine (reported 2009).
Initiation of Phase III clinical trial for seasonal influenza A/H5N1 vaccine (reported 2011).
Quality management system certification referenced across company materials (ISO 9001:2015).
Documented international cooperation and technology transfer agreements to support vaccine development and supply (partnerships with international organizations and manufacturers).
Completion of a registration dossier for an inactivated Vero-cell Japanese encephalitis vaccine with expected use projected in 2025 (reported by company R&D page).
Multiple state awards and labor medals and ministerial commendations documented across company history.
Completed Phase II clinical trial for a seasonal influenza A/H5N1 vaccine (reported 2009).
Initiation of Phase III clinical trial for seasonal influenza A/H5N1 vaccine (reported 2011).
Quality management system certification referenced across company materials (ISO 9001:2015).
Documented international cooperation and technology transfer agreements to support vaccine development and supply (partnerships with international organizations and manufacturers).
Completion of a registration dossier for an inactivated Vero-cell Japanese encephalitis vaccine with expected use projected in 2025 (reported by company R&D page).
Multiple state awards and labor medals and ministerial commendations documented across company history.